Prot# SG030-0003: A Phase II Multi-Dose Study of SGN-30 (anti-CD30 mAb) in Patients with Refractory or Recurrent Hodgkin's Disease or Anaplastic Large Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date11/17/049/1/11

Funding

  • Seattle Genetics, Inc. (SG030-0003)